

# PRODUCT INFORMATION

## Xamoterol (hemifumarate)

Item No. 24267

CAS Registry No.: 73210-73-8

Formal Name: N-[2-[[2-hydroxy-3-(4-hydroxyphenoxy)propyl]amino]ethyl]-4-morpholinecarboxamide, (E)-2-butenedioate (2:1)

Synonym: ICI 118587

MF:  $C_{16}H_{25}N_3O_5 \cdot 1/2 C_4H_4O_4$

FW: 397.4


Purity:  $\geq 98\%$

UV/Vis.:  $\lambda_{max}$ : 289 nm

Supplied as: A crystalline solid

Storage:  $-20^\circ C$

Stability:  $\geq 4$  years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

Xamoterol (hemifumarate) is supplied as a crystalline solid. A stock solution may be made by dissolving the xamoterol (hemifumarate) in the solvent of choice, which should be purged with an inert gas. Xamoterol (hemifumarate) is soluble in the organic solvent DMSO. It is also soluble in water. The solubility of xamoterol (hemifumarate) in DMSO and water is approximately 100 and 50 mM, respectively. We do not recommend storing the aqueous solution for more than one day.

### Description

Xamoterol is a partial agonist of  $\beta_1$ -adrenergic receptors ( $\beta_1$ -ARs) with an  $EC_{50}$  value of 80 nM for the generation of cyclic AMP (cAMP) in neonatal rat cardiomyocyte cultures.<sup>1</sup> It increases spontaneous contraction of isolated rat right atria ( $EC_{50} = 4.67$  nM).<sup>2</sup> *In vivo*, xamoterol increases heart rate in beagle dogs ( $ED_{50} = 3.2$   $\mu g/kg$ ) and in a rat model of spontaneous heart failure ( $ED_{50} = 6$   $\mu g/kg$ ), an effect that is reversed by the selective  $\beta_1$ -AR antagonist betaxolol (Item No. 18625) but not the selective  $\beta_2$ -AR antagonist ICI 118551 (Item No. 15591).<sup>1,3</sup> Formulations containing xamoterol have been used in the treatment of heart failure.

### References

1. Willette, R.N., Aiyar, N., T.-L., Y., *et al.* *In vitro* and *in vivo* characterization of intrinsic sympathomimetic activity in normal and heart failure rats. *J. Pharmacol. Exp. Ther.* **289**(1), 48-53 (1999).
2. Kowalski, M.T., Haworth, D., Lu, X., *et al.* Comparison of the effects of xamoterol and isoprenaline on rat cardiac  $\beta$ -adrenoceptors: Studies of function and regulation. *Br. J. Pharmacol.* **99**(1), 27-30 (1990).
3. Nuttall, A. and Snow, H.M. The cardiovascular effects of ICI 118,587: A  $\beta_1$ -adrenoceptor partial agonist. *Br. J. Pharmacol.* **77**(2), 381-388 (1982).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 11/28/2022

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897  
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM